JP2020065488A - 重症熱性血小板減少症候群（ｓｆｔｓ）ウイルス検出用プライマーセット - Google Patents
重症熱性血小板減少症候群（ｓｆｔｓ）ウイルス検出用プライマーセット Download PDFInfo
- Publication number
- JP2020065488A JP2020065488A JP2018200239A JP2018200239A JP2020065488A JP 2020065488 A JP2020065488 A JP 2020065488A JP 2018200239 A JP2018200239 A JP 2018200239A JP 2018200239 A JP2018200239 A JP 2018200239A JP 2020065488 A JP2020065488 A JP 2020065488A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- primer set
- sfts
- primer
- sfts virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 7
- 206010043554 thrombocytopenia Diseases 0.000 title claims abstract description 4
- 208000011580 syndromic disease Diseases 0.000 title claims abstract 3
- 238000001514 detection method Methods 0.000 title claims description 19
- 241001535172 Severe fever with thrombocytopenia virus Species 0.000 claims abstract description 53
- 238000007397 LAMP assay Methods 0.000 claims abstract description 24
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 23
- 239000013615 primer Substances 0.000 claims description 116
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 239000000523 sample Substances 0.000 claims description 27
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 26
- 230000003321 amplification Effects 0.000 claims description 23
- 239000003155 DNA primer Substances 0.000 claims description 22
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 150000007523 nucleic acids Chemical group 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 13
- 208000011361 Severe Fever with Thrombocytopenia Syndrome Diseases 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 abstract description 13
- 238000010586 diagram Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 15
- 238000005259 measurement Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 8
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 102100034343 Integrase Human genes 0.000 description 7
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000001668 nucleic acid synthesis Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000138 intercalating agent Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000238876 Acari Species 0.000 description 2
- 108010009595 Inorganic Pyrophosphatase Proteins 0.000 description 2
- 102100027050 Inorganic pyrophosphatase Human genes 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- -1 saliva Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101900234631 Escherichia coli DNA polymerase I Proteins 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 206010018999 Haemorrhage subcutaneous Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- 241000975322 Phytotoma Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000783701 SFTS virus HB29 Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 208000035056 Tick-Borne disease Diseases 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- ULHRKLSNHXXJLO-UHFFFAOYSA-L Yo-Pro-1 Chemical compound [I-].[I-].C1=CC=C2C(C=C3N(C4=CC=CC=C4O3)C)=CC=[N+](CCC[N+](C)(C)C)C2=C1 ULHRKLSNHXXJLO-UHFFFAOYSA-L 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- XZTWHWHGBBCSMX-UHFFFAOYSA-J dimagnesium;phosphonato phosphate Chemical compound [Mg+2].[Mg+2].[O-]P([O-])(=O)OP([O-])([O-])=O XZTWHWHGBBCSMX-UHFFFAOYSA-J 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
- C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018200239A JP2020065488A (ja) | 2018-10-24 | 2018-10-24 | 重症熱性血小板減少症候群（ｓｆｔｓ）ウイルス検出用プライマーセット |
| KR1020190132294A KR20200047384A (ko) | 2018-10-24 | 2019-10-23 | 중증열성혈소판감소증후군(sfts) 바이러스 검출용 프라이머 세트 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018200239A JP2020065488A (ja) | 2018-10-24 | 2018-10-24 | 重症熱性血小板減少症候群（ｓｆｔｓ）ウイルス検出用プライマーセット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020065488A true JP2020065488A (ja) | 2020-04-30 |
| JP2020065488A5 JP2020065488A5 (enExample) | 2021-07-26 |
Family
ID=70388494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018200239A Pending JP2020065488A (ja) | 2018-10-24 | 2018-10-24 | 重症熱性血小板減少症候群（ｓｆｔｓ）ウイルス検出用プライマーセット |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2020065488A (enExample) |
| KR (1) | KR20200047384A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022546507A (ja) * | 2019-08-29 | 2022-11-04 | インダストリー－アカデミック、コーオペレーション、ファウンデーション、チョスン、ユニバーシティー | 重症熱性血小板減少症候群ウイルス遺伝子検出用組成物及びこれを用いた重症熱性血小板減少症候群の診断方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102409468B1 (ko) * | 2020-08-31 | 2022-06-20 | 고려대학교 산학협력단 | 중증열성혈소판감소증후군 바이러스 검출용 루프매개등온증폭반응 프라이머 세트 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008259510A (ja) * | 2003-10-22 | 2008-10-30 | Toshiba Corp | 標的核酸配列の検出方法 |
| CN102618669A (zh) * | 2012-04-12 | 2012-08-01 | 中国人民解放军济南军区联勤部疾病预防控制中心 | 发热伴血小板减少综合症布尼亚病毒环sftsv介导等温扩增快速检测试剂盒及方法 |
| WO2013065574A1 (ja) * | 2011-10-31 | 2013-05-10 | 栄研化学株式会社 | 標的核酸の検出法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6654865B2 (ja) | 2015-11-12 | 2020-02-26 | 日東電工株式会社 | 非晶質透明導電性フィルム、ならびに、結晶質透明導電性フィルムおよびその製造方法 |
| CN105296674A (zh) | 2015-12-03 | 2016-02-03 | 江苏省疾病预防控制中心 | 发热伴血小板减少综合症病毒检测试剂盒及制备方法 |
| CN106191307A (zh) | 2016-07-14 | 2016-12-07 | 江苏省疾病预防控制中心 | 一种新布尼亚病毒检测试剂盒 |
| KR102070704B1 (ko) | 2018-01-08 | 2020-01-29 | 에스케이실트론 주식회사 | 슬러리 냉각장치 및 그를 구비한 슬러리 공급 시스템 |
-
2018
- 2018-10-24 JP JP2018200239A patent/JP2020065488A/ja active Pending
-
2019
- 2019-10-23 KR KR1020190132294A patent/KR20200047384A/ko not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008259510A (ja) * | 2003-10-22 | 2008-10-30 | Toshiba Corp | 標的核酸配列の検出方法 |
| WO2013065574A1 (ja) * | 2011-10-31 | 2013-05-10 | 栄研化学株式会社 | 標的核酸の検出法 |
| CN102618669A (zh) * | 2012-04-12 | 2012-08-01 | 中国人民解放军济南军区联勤部疾病预防控制中心 | 发热伴血小板减少综合症布尼亚病毒环sftsv介导等温扩增快速检测试剂盒及方法 |
Non-Patent Citations (3)
| Title |
|---|
| ARCHIVES OF VIROLOGY, vol. 157, JPN6022025803, 2012, pages 1779 - 1783, ISSN: 0004811692 * |
| JOURNAL OF CLINICAL MICROBIOLOGY, vol. 52, no. 2, JPN6022025802, 2014, pages 531 - 535, ISSN: 0004811691 * |
| JOURNAL OF VIROLOGICAL METHODS, vol. 194, JPN6022025801, 2013, pages 21 - 25, ISSN: 0004811690 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022546507A (ja) * | 2019-08-29 | 2022-11-04 | インダストリー－アカデミック、コーオペレーション、ファウンデーション、チョスン、ユニバーシティー | 重症熱性血小板減少症候群ウイルス遺伝子検出用組成物及びこれを用いた重症熱性血小板減少症候群の診断方法 |
| JP7360752B2 (ja) | 2019-08-29 | 2023-10-13 | インダストリー－アカデミック、コーオペレーション、ファウンデーション、チョスン、ユニバーシティー | 重症熱性血小板減少症候群ウイルス遺伝子検出用組成物及びこれを用いた重症熱性血小板減少症候群の診断方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200047384A (ko) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6983201B2 (ja) | 核酸プローブ | |
| JP5945271B2 (ja) | ニッキング酵素を用いたヘリカーゼ依存性等温増幅 | |
| WO2017212904A1 (ja) | 複数のプライマーセットを組み合わせたｌａｍｐ法を用いたアフリカ豚コレラウイルスの迅速検出法 | |
| JP7313537B2 (ja) | コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）の検出方法 | |
| KR102030244B1 (ko) | 뎅기 바이러스 검출용 올리고뉴클레오티드 세트 및 이의 용도 | |
| WO2018042598A1 (ja) | ジカウイルス検出用プライマーセット | |
| CN106893787A (zh) | 鉴别口蹄疫病毒和水泡性口炎病毒的二重荧光rt‑lamp检测引物组、试剂盒及其应用 | |
| US20160348189A1 (en) | Molecular detection of rna | |
| JP4603979B2 (ja) | Ｓａｒｓコロナウイルスの検出法 | |
| JP2020065488A (ja) | 重症熱性血小板減少症候群（ｓｆｔｓ）ウイルス検出用プライマーセット | |
| KR20100083133A (ko) | 레지오넬라속균 ｒＲＮＡ 증폭용 프라이머, 검출방법 및 검출 키트 | |
| KR102030245B1 (ko) | 치쿤군야 바이러스 검출용 올리고뉴클레오티드 세트 및 이의 용도 | |
| CN116042928B (zh) | 用于扩增和检测消化道病毒核酸序列的引物组 | |
| JP6803930B2 (ja) | Ｚｉｋａウイルス核酸を検出するための組成物および方法 | |
| JP7048819B2 (ja) | 一本鎖ｒｎａウイルスを検出する方法 | |
| JP6733215B2 (ja) | プライマー及びマイコプラズマ・ニューモニエの検出方法 | |
| TW202242140A (zh) | 引子修飾組、試劑盒、用於對恆溫環型核酸擴增的擴增產物進行轉錄的方法以及用於對目標核酸進行檢測的方法 | |
| JPWO2014027663A1 (ja) | ウシ白血病ウイルス検出用プライマーセット、及びその利用 | |
| JP2004344065A (ja) | オリゴヌクレオチド及びそれを用いた結核菌群の検出方法 | |
| WO2015114368A1 (en) | Method of detecting trichomonas vaginalis | |
| US9074248B1 (en) | Primers for helicase dependent amplification and their methods of use | |
| TWI885227B (zh) | 核酸偵測套組及核酸偵測方法 | |
| KR20190100675A (ko) | Sfts 바이러스 검출용 올리고뉴클레오티드 세트 및 이의 용도 | |
| JP7417985B2 (ja) | プライマーセット | |
| JP2008072951A (ja) | Ｌａｍｐ法を用いたサルモネラｏ４群の血清型迅速検出法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210511 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210511 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220628 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221220 |